---
document_datetime: 2026-02-13 15:20:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris.html
document_name: emtricitabine-rilpivirine-tenofovir-alafenamide-viatris.html
version: success
processing_time: 0.0955131
conversion_datetime: 2026-02-18 17:50:52.263731
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
# Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris

[RSS](/en/individual-human-medicine.xml/261740)

##### Authorised

This medicine is authorised for use in the European Union

emtricitabine / rilpivirine / tenofovir alafenamide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris is an antiviral medicine used in combination with other medicines to treat people infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is used in adults and adolescents aged 12 years and older who weigh at least 35 kg.

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris contains the active substances emtricitabine / rilpivirine / tenofovir and is a 'generic medicine'. This means that this medicine contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris is Odefsey.

Expand section

Collapse section

## How is Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris used?

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris can only be obtained with a prescription and treatment should be started by a doctor experienced in managing people with HIV infection.

The medicine is available as tablets to be taken by mouth once daily with food.

For more information about using Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris work?

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris contains three active substances. Tenofovir alafenamide is a 'prodrug' of tenofovir, meaning that it is converted into the active substance tenofovir in the body. Tenofovir and emtricitabine are related antiviral agents called reverse transcriptase inhibitors. Rilpivirine is an antiviral agent called non-nucleoside reverse transcriptase inhibitor.

All three active substances block the activity of reverse transcriptase, a virus enzyme that allows HIV-1 to replicate in the cells it has infected. By blocking this enzyme, this medicine reduces the amount of HIV-1 in the blood and keeps it at a low level.

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.

## How has Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Odefsey, and do not need to be repeated for Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris.

As for every medicine, the company provided studies on the quality of Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris?

Because Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris has been shown to have comparable quality and to be bioequivalent be comparable to Odefsey. Therefore, the Agency's view was that, as for Odefsey, the benefits of this medicine outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Odefsey also apply to Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris where appropriate.

As for all medicines, data on the use of Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris are continuously monitored. Suspected side effects reported with this medicine are carefully evaluated and any necessary action taken to protect patients.

## Other information about Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris received a marketing authorisation valid throughout the EU on 19 August 2025.

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris : EPAR - Medicine overview

Reference Number: EMA/216232/2025

English (EN) (190.59 KB - PDF)

**First published:** 25/09/2025

[View](/en/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-351)

български (BG) (163.13 KB - PDF)

**First published:**

25/09/2025

[View](/bg/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_bg.pdf)

español (ES) (139.06 KB - PDF)

**First published:**

25/09/2025

[View](/es/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (161.43 KB - PDF)

**First published:**

25/09/2025

[View](/cs/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (137.85 KB - PDF)

**First published:**

25/09/2025

[View](/da/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (141.33 KB - PDF)

**First published:**

25/09/2025

[View](/de/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (136.27 KB - PDF)

**First published:**

25/09/2025

[View](/et/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (165.71 KB - PDF)

**First published:**

25/09/2025

[View](/el/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_el.pdf)

français (FR) (140.43 KB - PDF)

**First published:**

25/09/2025

[View](/fr/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (156.84 KB - PDF)

**First published:**

25/09/2025

[View](/hr/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_hr.pdf)

italiano (IT) (137.47 KB - PDF)

**First published:**

25/09/2025

[View](/it/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (168.71 KB - PDF)

**First published:**

25/09/2025

[View](/lv/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (160.25 KB - PDF)

**First published:**

25/09/2025

[View](/lt/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (159.99 KB - PDF)

**First published:**

25/09/2025

[View](/hu/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (164.27 KB - PDF)

**First published:**

25/09/2025

[View](/mt/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (138.96 KB - PDF)

**First published:**

25/09/2025

[View](/nl/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (164.98 KB - PDF)

**First published:**

25/09/2025

[View](/pl/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_pl.pdf)

português (PT) (139.26 KB - PDF)

**First published:**

25/09/2025

[View](/pt/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_pt.pdf)

română (RO) (157.28 KB - PDF)

**First published:**

25/09/2025

[View](/ro/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (161.72 KB - PDF)

**First published:**

25/09/2025

[View](/sk/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (157.42 KB - PDF)

**First published:**

25/09/2025

[View](/sl/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (137.1 KB - PDF)

**First published:**

25/09/2025

[View](/fi/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (135.81 KB - PDF)

**First published:**

25/09/2025

[View](/sv/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_sv.pdf)

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris : EPAR - Risk management plan

English (EN) (280.87 KB - PDF)

**First published:** 25/09/2025

[View](/en/documents/rmp/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-risk-management-plan_en.pdf)

## Product information

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris : EPAR - Product information

English (EN) (402.75 KB - PDF)

**First published:** 25/09/2025

**Last updated:** 13/02/2026

[View](/en/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-41)

български (BG) (692.71 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/bg/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_bg.pdf)

español (ES) (361.44 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/es/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_es.pdf)

čeština (CS) (761.26 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/cs/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_cs.pdf)

dansk (DA) (345.88 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/da/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_da.pdf)

Deutsch (DE) (521.22 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/de/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_de.pdf)

eesti keel (ET) (591.89 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/et/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (720.39 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/el/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_el.pdf)

français (FR) (670.43 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/fr/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (484.4 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/hr/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_hr.pdf)

íslenska (IS) (361.08 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/is/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_is.pdf)

italiano (IT) (661.93 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/it/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (601.44 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/lv/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (552.91 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/lt/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_lt.pdf)

magyar (HU) (772.33 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/hu/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_hu.pdf)

Malti (MT) (789.79 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/mt/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (802.58 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/nl/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_nl.pdf)

norsk (NO) (334.27 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/no/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_no.pdf)

polski (PL) (682.27 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/pl/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_pl.pdf)

português (PT) (470.78 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/pt/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_pt.pdf)

română (RO) (810.05 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/ro/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (781.79 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/sk/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (474.56 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/sl/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_sl.pdf)

Suomi (FI) (349.31 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/fi/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_fi.pdf)

svenska (SV) (490.5 KB - PDF)

**First published:**

25/09/2025

**Last updated:**

13/02/2026

[View](/sv/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMA/VR/0000324454 12/02/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris : EPAR - All authorised presentations

English (EN) (55.33 KB - PDF)

**First published:** 25/09/2025

[View](/en/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-989)

български (BG) (43.63 KB - PDF)

**First published:**

25/09/2025

[View](/bg/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.81 KB - PDF)

**First published:**

25/09/2025

[View](/es/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.35 KB - PDF)

**First published:**

25/09/2025

[View](/cs/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (45.65 KB - PDF)

**First published:**

25/09/2025

[View](/da/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (53.86 KB - PDF)

**First published:**

25/09/2025

[View](/de/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.87 KB - PDF)

**First published:**

25/09/2025

[View](/et/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.24 KB - PDF)

**First published:**

25/09/2025

[View](/el/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (46.29 KB - PDF)

**First published:**

25/09/2025

[View](/fr/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (41.81 KB - PDF)

**First published:**

25/09/2025

[View](/hr/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.74 KB - PDF)

**First published:**

25/09/2025

[View](/is/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.17 KB - PDF)

**First published:**

25/09/2025

[View](/it/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.11 KB - PDF)

**First published:**

25/09/2025

[View](/lv/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (39.83 KB - PDF)

**First published:**

25/09/2025

[View](/lt/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (37.08 KB - PDF)

**First published:**

25/09/2025

[View](/hu/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.38 KB - PDF)

**First published:**

25/09/2025

[View](/mt/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (42.56 KB - PDF)

**First published:**

25/09/2025

[View](/nl/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.23 KB - PDF)

**First published:**

25/09/2025

[View](/no/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (65.04 KB - PDF)

**First published:**

25/09/2025

[View](/pl/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.69 KB - PDF)

**First published:**

25/09/2025

[View](/pt/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.87 KB - PDF)

**First published:**

25/09/2025

[View](/ro/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (45.64 KB - PDF)

**First published:**

25/09/2025

[View](/sk/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.04 KB - PDF)

**First published:**

25/09/2025

[View](/sl/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (18.24 KB - PDF)

**First published:**

25/09/2025

[View](/fi/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19 KB - PDF)

**First published:**

25/09/2025

[View](/sv/documents/all-authorised-presentations/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris Active substance

- emtricitabine
- rilpivirine hydrochloride
- tenofovir alafenamide fumarate

International non-proprietary name (INN) or common name

- emtricitabine
- rilpivirine
- tenofovir alafenamide

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR19

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100 000 HIV 1 RNA copies/mL (see sections 4.2, 4.4 and 5.1).

## Authorisation details

EMA product number EMEA/H/C/006491

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Dublin 15 Ireland

Opinion adopted 19/06/2025 Opinion status Positive Marketing authorisation issued 19/08/2025

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.24 KB - PDF)

**First published:** 13/02/2026

[View](/en/documents/procedural-steps-after/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/200896/2025

English (EN) (1.31 MB - PDF)

**First published:** 25/09/2025

[View](/en/documents/assessment-report/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris

Adopted

Reference Number: EMA/CHMP/200894/2025

English (EN) (163.43 KB - PDF)

**First published:** 20/06/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabine-rilpivirine-tenofovir-alafenamide-viatris_en.pdf)

#### News on Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 June 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-june-2025) 20/06/2025

**This page was last updated on** 13/02/2026

## Share this page

[Back to top](#main-content)